- Exchanges
- BSE, NSE
- Industry
- Pharmaceuticals
- Issue
- Book building
Concord Biotech IPO
₹942.80
+27.23% on listing
Listing-day close · NSE · 18 Aug 2023 · issue price ₹741
Concord Biotech’s ₹1,551 crore IPO was priced at ₹741 a share. It listed on the NSE on 18 Aug 2023 and closed its first day at ₹942.80, up 27.23% on the issue price.
Timeline
- Opens
- Closes
- Allotment
- Refunds
- Shares in demat
- Listing
Issue details
- Issue size
- ₹1,551 Cr
- Fresh issue
- —
- Offer for sale
- ₹1,551 Cr
- Lot size
- 20 shares
- Minimum investment
- ₹14,820
- Face value
- ₹1
- Registrar
- MUFG Intime India
Subscription
| Category | Shares offered | Times subscribed |
|---|---|---|
| Total | — | 17.64× |
Overall, from the basis of allotment.
Financials and valuation
- Market cap (post-issue)
- ₹7,752 Cr
- P/E (post-issue)
- 32.3
- EPS (post-issue)
- ₹22.95
- Price to book
- 6.0
- ROE
- 20.06%
- ROCE
- 24.27%
- PAT margin
- 28.14%
- Promoter holding
- 44.08% → 44.08%
Financials as of 31 Mar 2023, from the offer documents.
Listing
- Listing date
- 18 Aug 2023
- Issue price
- ₹741
- Open
- ₹900.05
- High
- ₹987.70
- Low
- ₹900.05
- Close
- ₹942.80
Listing day on the NSE. The close was +27.23% on the issue price.
CONCORDBIO share price todayFAQs
When did the Concord Biotech IPO open and close?
It opened on 4 Aug 2023 and closed on 8 Aug 2023.
What was the Concord Biotech IPO price?
The price band was ₹705–741 a share. The final issue price was ₹741.
What is the lot size and minimum investment?
One lot is 20 shares, ₹14,820 at ₹741 a share. Retail investors apply in whole lots.
How much did Concord Biotech raise?
₹1,551 crore: ₹1,551 crore offered by existing shareholders.
How many times was the Concord Biotech IPO subscribed?
17.64 times overall.
How did Concord Biotech list?
It listed on the NSE on 18 Aug 2023 at ₹900.05 and closed the day at ₹942.80, up 27.23% on the ₹741 issue price.
Who is the registrar of the Concord Biotech IPO?
MUFG Intime India handles the allotment, refunds and credit of shares.
For information only. Not investment advice or a research report.
Full disclaimerSee how an IPO fits your plan
Armor checks every holding against your goals, risk and timeline.
Get the app